Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05491733 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of APX001 High-load and Low-load Tablets
A Phase 1 study of Invasive Fungal Infections, sponsored by Basilea Pharmaceutica.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05491733: Completed Phase 1 study of Invasive Fungal Infections, sponsored by Basilea Pharmaceutica.
NCT05491733 is a Phase 1 study of Invasive Fungal Infections that has completed, run by Basilea Pharmaceutica. The registered enrollment target is 18 participants, below the 48-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05491733, a Phase 1 study of Invasive Fungal Infections, has completed, sponsored by Basilea Pharmaceutica.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
Conditions Studied
Interventions
- DRUG APX001
- DRUG APX001A
Study Locations (1)
Utah
- Pharmaceuticals Research Associates, Inc - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-03-02 |
| Est. Completion | 2021-06-23 |
| Phase | Phase 1 |
What the finished NCT05491733 record still lists
NCT05491733 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 48-participant average among 4 other Invasive Fungal Infections trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Invasive Fungal Infections appearing as the primary indexed condition, and to 2 interventions - of which APX001 is the first listed.
NCT05491733 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05491733 about?
NCT05491733 is a clinical study titled "A Bioequivalence Study of APX001 High-load and Low-load Tablets". A study to learn about the bioequivalence (the biochemical similarity of two medicines that share the same active ingredient and desired outcome for patients) of the study medicine called APX001 in healthy participants.
What is the current status of trial NCT05491733?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-03-02. Estimated completion is 2021-06-23.
What conditions does trial NCT05491733 study?
This clinical trial studies the following conditions: Invasive Fungal Infections.
What interventions are being tested in trial NCT05491733?
The interventions under investigation include: APX001 (DRUG), APX001A (DRUG).
Who is sponsoring clinical trial NCT05491733?
This trial is sponsored by Basilea Pharmaceutica, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05491733 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Fungal Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
COMPLETED
-
Evaluation of NGS for Detection and Follow-up of Fungal Pathogens in Immunocompromised Pediatric Patients
COMPLETED
-
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
COMPLETED · Phase 3
-
Endemic Mycoses Treatment With SUBA-itraconazole vs Itraconazole
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI